Quelles évolutions dans la prise en charge des tumeurs digestives ?

This article aimed to review third line therapeutic to review third line therapeutic options in patients with metastatic colorectal cancer, therapeutic strategies in the event of metastatic gastric cancer and first line treatments for metastatic pancreatic cancer. Following the results of the SUNLIGHT study, the trifluridine/tipiracil plus bévacizumab combination should become the new third line standard for metastatic colorectal cancers. Performing multiple tumor biopsies to assess several biomarkers (HER2, dMMR/pMMR, CPS, Claudine 18.2) essential for choosing the best first-line therapeutic combination is becoming essential in gastric cancers. In patients with metastatic pancreatic cancer, the NAPOLI-3 study is positive and positions the NALIRIFOX protocol as a new option of choice in 1st line. In these same patients, in the absence of a validated predictive biomarker, the interest of a sequential strategy with alternation of two chemotherapy protocols continues to be evaluated in ongoing phase 2 studies. [ABSTRACT FROM AUTHOR]